Daily Ards Research Analysis
Three studies inform critical care and COVID-19-related respiratory science today: a multicenter cohort shows mass ICU transfers during COVID-19 surges were associated with markedly lower 28-day ICU mortality; an exploratory clinical study links higher IL-24 levels to milder COVID-19; and a binational case-control study finds small but measurable cognitive slowing in post-COVID syndrome.
Summary
Three studies inform critical care and COVID-19-related respiratory science today: a multicenter cohort shows mass ICU transfers during COVID-19 surges were associated with markedly lower 28-day ICU mortality; an exploratory clinical study links higher IL-24 levels to milder COVID-19; and a binational case-control study finds small but measurable cognitive slowing in post-COVID syndrome.
Research Themes
- Critical care surge strategies and systems-level outcomes
- Immunologic biomarkers and COVID-19 pathophysiology
- Long-COVID neurocognitive sequelae
Selected Articles
1. Mass Medical Evacuations to Decrease the Intensive Care Burden: Results From the TRANSCOV Cohort Study.
In a multicenter matched retrospective cohort during France’s first COVID-19 wave, inter-ICU transfers were associated with a sevenfold lower 28-day ICU case fatality (adjusted IRR 0.14). Despite longer ICU stays and higher delirium/psychiatric events in transferred patients, the findings suggest decongesting overwhelmed ICUs confers substantial survival benefit beyond selection effects.
Impact: This study provides robust systems-level evidence that mass inter-ICU transfers can mitigate mortality during surges, informing disaster preparedness and critical care resource allocation.
Clinical Implications: During overwhelming ICU demand, early organized inter-ICU transfers should be considered to reduce case fatality, alongside measures to minimize delirium risk and manage longer ICU stays.
Key Findings
- 28-day ICU case fatality was approximately sevenfold lower in transferred patients (adjusted IRR 0.14; 95% CI 0.10–0.19).
- Transferred patients had longer ICU stays and more delirium/psychiatric disorders and neuromuscular blockade exposure.
- Acute kidney injury occurred more frequently in control patients (51.5% vs 37.7%, P < .0001).
- Baseline severity and comorbidities were similar, but transferred patients were lighter and more autonomous.
Methodological Strengths
- Multicenter matched retrospective cohort with time-synchronized controls from the same origin ICUs
- Adjusted analysis reporting incidence rate ratios with confidence intervals
Limitations
- Retrospective design with potential selection of healthier patients for transfer
- Generalizability beyond pandemic surge settings is uncertain
Future Directions: Prospective or quasi-experimental evaluations of transfer strategies, integration of capacity modeling, and assessment of neuropsychiatric outcomes mitigation in transferred patients.
BACKGROUND: In a context of overwhelming demand, mass transfers between ICUs were organized in France during the first COVID-19 epidemic wave (spring 2020). According to early reports, transferred patients experienced a 3- to 4-fold lower ICU case fatality. It is not known whether this difference stems only from the selection of healthier patients for transfer. RESEARCH QUESTION: Is the 28-day ICU case fatality of transferred patients different from that of matched control (not transferred) patients? STUDY DESIGN AND METHODS: This was a multicenter retrospective cohort study that included 285 transferred patients and 667 control (not transferred) patients admitted simultaneously (± 2 days) to the same origin ICU and were alive 5 days after the transfer date. The 28-day ICU case fatality and clinical events during ICU stay were compared in transferred and control patients. RESULTS: At ICU admission, age, COVID-19 severity, comorbidities, and Simplified Acute Physiology Score II were similar, but transferred patients were lighter (81 vs 89 kg, P < .0001) and more autonomous than the matched control patients (64.5% vs 55.0%, P = .01). Case fatality was approximately 7-fold lower in transferred patients (adjusted incidence rate ratio, 0.14; 95% CI, 0.10-0.19). ICU stay was longer and delirium, psychiatric disorders, and neuromuscular blockade exposure were more frequent in transferred patients than control patients. Conversely, acute kidney injury was more frequent in control patients (51.5% vs 37.7%, P < .0001). INTERPRETATION: Although the selection of healthier patients likely contributed to better survival, removal from an overcrowded care environment probably also explains the large survival benefit associated with transfer. By reducing workload, mass transfers might have also benefited patients who remained in origin ICUs. Organizing mass transfers as early as possible may be an appropriate strategy for mitigating the impact of an overwhelming intensive care demand.
2. IL-24 in COVID-19 Patients: Correlations with Disease Progression.
In a prospective two-center cross-sectional study of 41 COVID-19 patients with 88 serial samples, IL-24 serum levels measured by ELISA were higher in ambulant mild cases than in hospitalized patients. The work implicates IL-24 in disease modulation and motivates further validation as a biomarker of disease activity.
Impact: Identifying cytokine signatures linked to clinical severity can refine risk stratification and therapeutic targeting in COVID-19 and related respiratory failure.
Clinical Implications: IL-24 may aid in distinguishing milder from more severe disease states; however, clinical use requires validation in larger, longitudinal cohorts and assessment of added value over standard markers.
Key Findings
- Prospective bi-center cross-sectional study enrolled 41 patients and collected 88 serial blood samples.
- IL-24 serum levels (ELISA) were higher in ambulant mild COVID-19 compared to hospitalized (critical/severe/moderate) cases.
- Patients were classified by WHO severity criteria; analyses included non-parametric tests and correlations.
Methodological Strengths
- Prospective design with multicenter enrollment
- Serial sampling enabling within-patient assessment across phases
Limitations
- Small sample size and cross-sectional nature limit causal inference
- Heterogeneity of sampling timing (acute vs convalescent) and lack of external validation
Future Directions: Validate IL-24 as a prognostic/monitoring biomarker in larger longitudinal cohorts, define thresholds, and integrate with multiplex cytokine panels.
Interleukin-24 (IL-24) is a cytokine known for its role in immune regulation and apoptosis, with potential implications in viral infections like COVID-19. This study aimed to investigate the association between IL-24 serum levels and the severity of COVID-19 disease. In this prospective bi-center cross-sectional study, we enrolled 41 COVID-19 patients from two hospitals in Germany. Serial blood samples were collected from a subset of patients, resulting in 88 total blood samples. Patients were categorized into critical, severe, moderate, and mild disease groups based on WHO criteria. IL-24 serum levels were measured during the acute or convalescent phase using an ELISA assay. Inflammatory markers, and kidney and liver function parameters were also evaluated. Statistical analysis included non-parametric tests and correlation analysis. Elevated IL-24 serum levels were observed in ambulant patients (mild disease), compared to hospitalized patients (critical, severe, moderate disease,
3. Cognitive sequelae in post-COVID-syndrome: a Danish-Swedish case-control study.
In a Danish–Swedish case-control study (181 PCS vs 155 recovered controls), PCS was associated with broadly reduced cognitive scores, with processing speed most affected and greater deficits among those infected early in the pandemic. Psychological distress and grip strength were altered in PCS but were not decisively linked to cognitive performance.
Impact: Provides controlled evidence quantifying cognitive slowing in PCS, informing patient counseling and the design of rehabilitation strategies.
Clinical Implications: Clinicians should anticipate mild processing speed deficits in PCS, especially after early-pandemic infections, and incorporate targeted cognitive assessment and rehabilitation where appropriate.
Key Findings
- Recruited 181 PCS cases and 155 recovered controls from long-COVID clinics in Denmark and Sweden.
- PCS patients showed reduced cognitive performance across domains, with processing speed most affected.
- Greater processing speed deficits were observed in those infected early in the pandemic.
- Psychological distress and hand grip strength were affected in PCS but were not decisively associated with cognitive scores.
Methodological Strengths
- Case-control design with adjustment for key confounders specified a priori
- Binational recruitment and standardized cognitive and psychometric testing
Limitations
- Observed effects were small and of limited clinical significance
- Recruitment from specialty long-COVID clinics may introduce selection bias
Future Directions: Longitudinal follow-up to determine persistence and functional impact of processing speed deficits, and trials of targeted cognitive rehabilitation.
BACKGROUND: While patients with post-COVID syndrome (PCS) suffer from cognitive deficits few studies directly compare patients with PCS to subjects recovered after an infection with the 'Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)'. OBJECTIVES: To investigate cognitive performance adjusting for age, increasing body-mass-index (BMI), smoking, years of education, gender and hospitalisation while infected in patients with PCS compared to controls fully recovered. Secondly, to stratify cognitive performance based on the SARS-CoV-2 virus strain (variant of concern 'VOC') causing the infection. Thirdly, to assess whether patients with PCS have increased levels of psychological distress and affected hand grip strength as both are associated with cognitive performance. METHODS: A Danish-Swedish case-control study we recruited adult patients (18-75 years) with PCS from long-COVID outpatient clinics in Region Zealand Denmark and Skåne County Sweden. Participants had confirmed SARS-CoV-2 infection >12 weeks prior to inclusion and healthy control subjects had recovered completely. All study participants were exposed to cognitive tests, Kessler's psychological distress scale (K10) and tested with a hand-dynamometer. RESULTS: Recruiting 181 cases and 155 control subjects, patients with PCS had reduced cognitive performance scores on all domains though hardly clinically significant. Reduced processing speed was impacted the most with patients infected early in the pandemic exhibiting greater deficits. CONCLUSION: PCS was associated with reduced cognitive processing speed compared to fully recovered controls with those infected early in the pandemic having greater deficits. Psychological distress and hand grip strength were affected in patients with PCS, but not decisively associated with cognitive performance.